A Study to Look at Whether Etrasimod Improves Ulcerative Colitis Symptoms and Whether it is Safe After 12-weeks of Treatment in Japanese Participants.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Week Dose-Ranging Study to Assess the Efficacy and Safety of
Etrasimod in Japanese Participants with Moderately to Severely Active Ulcerative Colitis